Brief: Enlivex Announces Allowance Of New U.S. Patent Covering Allocetra Immunotherapy
25/08/2020 13:57
Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES ALLOWANCE OF NEW U.S. PATENT COVERING
ALLOCETRA IMMUNOTHERAPY
Source text for Eikon: ID:nGNX3Cc3wx
Further company coverage: ENLV.TA
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment